A Study on Glucose Control and Quality of Life Improvement in Type 1 Diabetes Patients Following Switching from SAP770G to 780G A Prospective Observational Study

A Study on Glucose Control and Quality of Life Improvement in Type 1 Diabetes Patients Following Switching from SAP770G to 780G A Prospective Observational Study - SAP780G Switchover Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000060792

Enrollment

Registered

2026-03-02

Start date

2024-05-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The inclusion criteria were a diagnosis of type 1 diabetes and treatment with the MiniMed 770G system.

Exclusion criteria

Exclusion criteria: Patients for whom participation in this study is difficult due to concomitant severe liver disease. Patients deemed inappropriate for participation by the principal investigator or subinvestigators for any other reason.

Design outcomes

Primary

Measure	Time frame
Change in average blood glucose from baseline 12 weeks after switching to 780G	—

Secondary

Measure	Time frame
Changes at 4 weeks, 12 weeks, and 24 weeks from the start of the study Weight, waist circumference, BMI Blood pressure, pulse rate Other blood and urine tests Daily blood glucose variability indices by treatment 24-hour average blood glucose Percentage of time in target range (TIR; time spent within 70-180 mg/dL) Length of time with blood glucose below 70 mg/dL (TBR; Percentage of time below target range) Length of time with blood glucose above 180 mg/dL (TAR; Percentage of time above target range) Daily blood glucose variability index Hourly blood glucose AUC, MAGE, SD, MODD Association with patient background and laboratory values affecting the above data Patient questionnaires related to diabetes treatment satisfaction and QOL Association with patient background and laboratory values affecting the above data Patient background and clinical laboratory values affecting the above data	—

Measure

Time frame

Changes at 4 weeks, 12 weeks, and 24 weeks from the start of the study Weight, waist circumference, BMI Blood pressure, pulse rate Other blood and urine tests Daily blood glucose variability indices by treatment 24-hour average blood glucose Percentage of time in target range (TIR; time spent within 70-180 mg/dL) Length of time with blood glucose below 70 mg/dL (TBR; Percentage of time below target range) Length of time with blood glucose above 180 mg/dL (TAR; Percentage of time above target range) Daily blood glucose variability index Hourly blood glucose AUC, MAGE, SD, MODD Association with patient background and laboratory values affecting the above data Patient questionnaires related to diabetes treatment satisfaction and QOL Association with patient background and laboratory values affecting the above data Patient background and clinical laboratory values affecting the above data

—

Countries

Japan

Contacts

Public ContactYUKI OE

Kushiro Red Cross Hospital Department of Internal Medicine

o-e.yuki@med.hokudai.ac.jp0154-22-7171

Outcome results